Guardant Health beat revenue by 6.5% on 44% growth but missed EPS as it poured cash into Shield, the blood-based colorectal cancer test that just surged 250% in quarterly revenue on UnitedHealth coverage and American Cancer Society endorsement. The company raised full-year guidance to $1.34–$1.36 billion, projecting Shield to deliver 270,000–285,000 tests this year.
Guardant Health :
GH
GH
Stock Data
$163.35
$1.75 (1.06%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
DIAGNOSTICS & RESEARCH
Guardant Health Inc is a pioneer in precision oncology, offering a wide range of blood and tissue tests to support cancer diagnosis and treatment. With products like Guardant360 and GuardantOMNI, the company focuses on providing detailed insights into cancer evolution and treatment resistance. It also offers software solutions like GuardantConnect for linking patients to clinical studies, and Guardant Galaxy, an AI-driven platform for enhancing biomarker detection. Partnering with Illumina, Inc., Guardant Health is at the forefront of cancer research, leveraging its advanced technologies to improve patient outcomes. Founded in 2011, its headquarters are in Palo Alto, California.
Latest Activity
All Guardant Health Articles
8 Articles